Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

INHANCE Stemless Reverse Shoulder IDE

2. November 2026 aktualisiert von: DePuy Orthopaedics

Randomisierte, prospektive, multizentrische Studie des INHANCE Stemless Total Reverse Shoulder System

2:1 Randomized, Controlled, Multi-Center, Prospective, Pre-Market Study of the INHANCE Stemless Reverse Cementless Total Shoulder.

Studienübersicht

Status

Aktiv, nicht rekrutierend

Intervention / Behandlung

Detaillierte Beschreibung

There is one primary effectiveness endpoint and there are three primary safety endpoints:

  1. Primary effectiveness endpoint - Adjusted Constant-Murley Change from Baseline (ACM CFB) at 2 years post-operative

  2. Primary safety endpoint(s):

    1. No revision, removal, reoperation, supplemental fixation, or other intervention for any system component
    2. No humeral or glenoid radiolucent line >2 mm is present in 50% or more zones at 2 years
    3. No conclusive evidence of migration and tilt (>5mm migration and >10° tilt) of the humeral or glenoid component at 2 years

The study will be successful if the primary effectiveness endpoint non-inferiority analysis is successfully demonstrated, and no significant difference is seen on any of the 3 primary safety endpoints.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

168

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Florida
      • Atlantis, Florida, Vereinigte Staaten, 33462
        • Orthopedic Center of Palm Beach County
    • Massachusetts
      • Waltham, Massachusetts, Vereinigte Staaten, 02451
        • Boston Bone & Joint Institute BBJI Formerly BSSC
    • Michigan
      • Grand Rapids, Michigan, Vereinigte Staaten, 49503
        • Trinity Health Grand Rapids
    • Missouri
      • Columbia, Missouri, Vereinigte Staaten, 65201
        • Missouri Orthopaedic Institute (MOI)
    • North Carolina
      • Charlotte, North Carolina, Vereinigte Staaten, 28207
        • OrthoCarolina Research Institute Charlotte
      • Raleigh, North Carolina, Vereinigte Staaten, 27609
        • Duke Orthopaedics of Raleigh
    • Ohio
      • Akron, Ohio, Vereinigte Staaten, 44333
        • Crystal Clinic Orthopaedic Center
      • Cincinnati, Ohio, Vereinigte Staaten, 45219
        • Lindner Research Center
      • Cleveland, Ohio, Vereinigte Staaten, 44195
        • The Cleveland Clinic Foundation
    • Oregon
      • Eugene, Oregon, Vereinigte Staaten, 97401
        • Slocum Center for Orthopaedics and Sports Medicine
    • Pennsylvania
      • Bethlehem, Pennsylvania, Vereinigte Staaten, 18015
        • St. Luke's University Health Network
      • Philadelphia, Pennsylvania, Vereinigte Staaten, 19107
        • Rothman Orthopaedics Institute
    • Tennessee
      • Columbia, Tennessee, Vereinigte Staaten, 38401
        • MTBJ a division of Tennessee Orthaepedic Alliance
    • Utah
      • Salt Lake City, Utah, Vereinigte Staaten, 84108
        • University of Utah
    • Virginia
      • Fredericksburg, Virginia, Vereinigte Staaten, 22408
        • Mary Washington Orthopedics in affiliation with FOA

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

22 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  1. Individuals requiring reverse total shoulder replacement for a severely painful, disabling, arthritic joint (i.e. osteoarthritis, post-traumatic arthritis and rotator cuff arthropathy).
  2. Individuals who are anatomically and structurally suited to receive the implants and have a functional deltoid muscle.
  3. Individuals who are able to read and comprehend the informed patient consent document and are willing and able to provide informed patient consent for participation in the study and have authorized the transfer of their information to DePuy Synthes.
  4. Individuals who are willing and able to return for follow-up as specified by the study protocol.
  5. Individuals who are a minimum age of 22 years at the time of consent.
  6. Individuals who are willing and able to complete the Patient Reported Outcome Measure questionnaires (PROMs) as specified by the study protocol.

Exclusion Criteria:

  1. BMI > 40 kg/m2
  2. Individuals have active, uncontrolled local infection or systemic infection.
  3. Patients who have not reached skeletal maturity, regardless of age.
  4. Either preoperatively or intraoperatively and per standard of care medical assessment, bone stock in the proximal humerus or glenoid fossa is determined to be inadequate for supporting the INHANCE humeral stemless components (NOTE: exclusion applies to both arms of the study, i.e., bone stock to be evaluated independent of randomized treatment assignment).
  5. Intraoperatively and per treating physician's assessment of bone quality, bone is determined to be too soft or porous to support the implant or that is too hard or brittle to allow for proper bone preparation and fixation, i.e. osteoporosis or sclerotic bone, or tumor(s) of the supporting bone structure, where there could be considerable migration of the prosthesis and/or a chance of fracture of the humerus or glenoid.
  6. Fractures of the proximal humerus that could compromise the fixation of the INHANCE reverse humeral stemless components.
  7. Patients who have undergone previous treatment on the study shoulder that may compromise fixation of the INHANCE reverse humeral stemless component.
  8. Revision of a failed hemi, total or reverse shoulder arthroplasty.
  9. Patient is receiving, or is scheduled to receive, treatment that the Investigator considers could affect bone quality, such as chemotherapy or high dose corticosteroids.
  10. Individuals who are bedridden per the Investigator's determination.
  11. Individuals that have participated in a clinical investigation with an investigational product (drug or device) in the last three months.
  12. Individuals currently involved in any personal injury litigation, medical-legal or worker's compensation claims.
  13. Individuals, in the opinion of the Investigator, who are drug or alcohol abusers or have psychological disorders that could affect their ability to complete patient reported questionnaires or be compliant with follow-up requirements.
  14. Patients with a known medical condition that the Investigator believes would impact the study outcomes (including, but not limited to osteomyelitis, Paget's disease, neuropathies such as Charcot's disease, metastatic or neoplastic disorders).
  15. Patient has a medical condition with less than 2 years life expectancy.
  16. Patients who are known to be pregnant or breastfeeding.
  17. Known polyethylene and/or metal sensitivity or allergy.
  18. Contralateral side has been enrolled in the study or has received a total shoulder operation within the last 6 months
  19. Otherwise determined by the investigator to be medically unsuitable for participation in this study
  20. Patient is a member of a vulnerable population (i.e., incarcerated individuals - those incarcerated for at least one month and considered to be an inmate)

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: INHANCE Stemless Reverse

INHANCE(TM) Stemless Reverse Total Shoulder

Uncemented Reverse Total Shoulder

Aktiver Komparator: INHANCE Stemmed Reverse

INHANCE(TM) Stemmed Reverse Total Shoulder

Uncemented Reverse Total Shoulder

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Constant Murley Score (CMS)
Zeitfenster: Pre-op, 2 years

Primary effectiveness endpoint - Adjusted Constant-Murley Change from Baseline (ACM CFB) at 2 years post-operative. The CMS is a 100 point scale, the higher the score, the higher the quality of the function. ACM will be obtained by dividing the raw score by the relative score.

Pre-op, 2 years
Removal of any system component
Zeitfenster: 2 year

No removal of any system component

2 year
Revision of any system component
Zeitfenster: 2 year

No revision of any system component

2 year
Reoperation of any system component
Zeitfenster: 2 year

No reoperation of any system component

2 year
Supplemental Fixation of any system component
Zeitfenster: 2 year

No supplemental fixation of any system component

2 year
Radiolucent Lines (Humeral & Glenoid)
Zeitfenster: 2 year

No humeral or glenoid radiolucent line greater than 2mm is present in 50% or more zones

2 year
Migration and Tilt (Humeral & Glenoid)
Zeitfenster: 2 year

No conclusive evidence of migration and tilt (greater than 5mm migration and greater than 10 degrees tilt) of the humeral or glenoid component

2 year

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Constant Murley Score (CMS)
Zeitfenster: Pre-op, 3-month, 6-month, 1 year, 2 year

Adjusted Constant-Murley Score at baseline and 3- and 6-months and 1- and 2-years post-operative. The CMS is a 100 point scale, the higher the score, the higher the quality of the function. ACM will be obtained by dividing the raw score by the relative score.

Pre-op, 3-month, 6-month, 1 year, 2 year
EQ-5D-5L and EQ-VAS
Zeitfenster: Pre-op, 3-month, 6-month, 1 year, 2 year

EQ-5D-5L Scores by dimension and EQ-VAS, at baseline and 3- and 6-months and 1- and 2-years post-operative. The value score generally ranges from less than 0 to 1, with higher scores indicating higher health utility. The EQ VAS records the subject's self-rated health from 0 (worst) to 100 (best).

Pre-op, 3-month, 6-month, 1 year, 2 year
Simple Shoulder Test
Zeitfenster: Pre-op, 3-month, 6-month, 1 year, 2 year

Simple Shoulder Test (SST) Scores at baseline and 3- and 6-months and 1- and 2-years post-operative. Scores range from 0 (worst) to 12 (best).

Pre-op, 3-month, 6-month, 1 year, 2 year
Single Assessment Numeric Evaluation (SANE) Score
Zeitfenster: Pre-op, 3-month, 6-month, 1 year, 2 year

Single Assessment Numeric Evaluation (SANE) Scores at baseline and 3- and 6-months and 1- and 2-years post-operative. The scale is 0 to 100 with 100 being "normal".

Pre-op, 3-month, 6-month, 1 year, 2 year
Survivorship
Zeitfenster: 2 year

Overall survivorship of the INHANCE Shoulder System at 2 years post-operative, where the system is deemed to be surviving if no components (humeral stem or stemless component, glenosphere, baseplate, liner, etc.) have been removed for any reason, will be presented using the Kaplan-Meier method.

2 year
Complications
Zeitfenster: 2 year

The type and frequency of all reportable adverse events (AEs) and device deficiencies in this study will be summarized, with distinction of serious AEs, device and procedure related AEs

2 year

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Constant Murley Score (CMS)
Zeitfenster: Pre-op, 3-month, 6-month, 1 year

Change from baseline adjusted Constant-Murley Score at 3- and 6-months and 1- year post-operative. The CMS is a 100 point scale, the higher the score, the higher the quality of the function. ACM will be obtained by dividing the raw score by the relative score.

Pre-op, 3-month, 6-month, 1 year
EQ-5D-5L and EQ-VAS
Zeitfenster: Pre-op, 3-month, 6-month, 1 year, 2 year

Change from baseline EQ-5D-5L Value Score and EQ-VAS, at 3- and 6-months and 1- and 2-years post-operative. The value score generally ranges from less than 0 to 1, with higher scores indicating higher health utility. The EQ VAS records the subject's self-rated health from 0 (worst) to 100 (best).

Pre-op, 3-month, 6-month, 1 year, 2 year
Simple Shoulder Test
Zeitfenster: Pre-op, 3-month, 6-month, 1 year, 2 year

Change from baseline SST Scores at 3- and 6-months and 1- and 2-years post-operative. Scores range from 0 (worst) to 12 (best).

Pre-op, 3-month, 6-month, 1 year, 2 year
Single Assessment Numeric Evaluation (SANE) Score
Zeitfenster: Pre-op, 3-month, 6-month, 1 year, 2 year

Change from baseline SANE Scores at 3- and 6-months and 1- and 2-years post-operative. The scale is 0 to 100 with 100 being "normal".

Pre-op, 3-month, 6-month, 1 year, 2 year
Range of Motion
Zeitfenster: Pre-op, 3-month, 6-month, 1 year, 2 year

Change from baseline range of motion at 3- and 6-months and 1- and 2-years post-operative

Pre-op, 3-month, 6-month, 1 year, 2 year

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

4. März 2025

Primärer Abschluss (Geschätzt)

10. November 2027

Studienabschluss (Geschätzt)

30. Oktober 2028

Studienanmeldedaten

Zuerst eingereicht

27. Februar 2024

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

15. März 2024

Zuerst gepostet (Tatsächlich)

21. März 2024

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

3. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

2. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • DSM202108
  • DSM202108 (Andere Kennung: DePuy Orthopaedics)

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Ja

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren